secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-09-21T20:20:00+00:00
Accession:  0001193125-26-396690
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports FY2026 net income $176.4M; Jemperli sales up 34% YoY
-----------------------------------------------------------------------

- Jemperli global net sales $644M (£480M) for six months ended Jun 30, 2026, +34% YoY; Q2 $331M, +26% YoY.
- FDA PDUFA Feb 2027 for Jemperli in dMMR/MSI-H rectal cancer; AZUR-1 interim results met primary cCR12 endpoint.
- GSK/Tesaro litigation: trial held Jul 14-17; post-trial hearing Oct 20; judgement expected Q4 2026/Q1 2027, seeking Jemperli reversion.
- Cash $164.1M at Jun 30, 2026 vs $211.6M at Dec 31, 2025; collaboration revenue $53.0M for six months.
- Net income from continuing ops $176.4M ($6.09 diluted EPS) for six months; $181.5M tax benefit from valuation allowance release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/0001193125-26-396690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab-20260921.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-396690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer